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DISCUSSION: In general, patients preferred home treat-
ment to clinic treatment, and felt strongly that oral che-
motherapy was more convenient and not less effective.
This study suggests that many patients with recurrent
ovarian cancer value their time away from a clinical set-
ting and prefer oral chemotherapy at home. The reason
why patients prefer oral therapy is convenience and effec-
tiveness.
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OBJECTIVES: To estimate the effect of major micro-
and macrovascular complications on resource use and
cost in diabetic type 2 patients in Germany. METHODS:
Estimates for complication subgroups were based on re-
sults from the CODE-2 cost of illness study. The German
arm of the study analyzed data on resource utilisation of
809 patients with diabetes type 2 for 1998. A stratified
random sampling technique also allowed analysis for
rare subgroups. Direct and indirect cost were analysed
from a sickness fund perspective. RESULTS: The analysis
indicates that overall cost rises dramatically with devel-
opment of complications. The major cost driver was hos-
pitalization (see table below). CONCLUSIONS: The
study demonstrates the substantial cost burden; this sug-
Patient Reported Preferences and Beliefs, 1  strongly 
agree
Questions Oral (n  22)
IV 
(n  11)
IV more effective 3.1 3.3
Pills more effective 3.4 4.0
IV at clinic convenient 2.6* 1.0*
Pills convenient 0.4 1.2
Prefer pills at home 2.1* 3.6*
Worry about IV line started 3.2* 4.6*
Worry over emesis with pills 3.4 3.8
Questions
No Preference 
(n  6) P-value
IV more effective 3.5
Pills more effective 3.3
IV at clinic convenient 2.2 P  0.003
Pills convenient 1.5 P  0.025
Prefer pills at home 2.5 P  0.002
Worry about IV line started 2.8
Worry over emesis with pills 2.3
gests cost savings by preventing micro- and macrovascu-
lar complications.
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Complications of Type 1 diabetes mellitus (DM) increase
costs to the healthcare provider. Age is correlated with
complications as well as costs. OBJECTIVE: To estimate
diabetes-related costs due to complications separately
from age. METHODS: Members with Type 1 DM were
selected by ETG group from PharMetric’s Integrated
Outcomes database during 1997. Charges to the mem-
ber’s MCO for ED, pharmacy, in- and out-patient services
were tallied over CY 1997. Members were classified: (1)
as having 0,1, or 1 complications (nephropathy, retin-
opathy, neuropathy, or CAD), and (2) by age: 18, 18–44,
45–64, or 65. A regression of age and gender on
ln(charges) was compared to a regression of age, gender,
and complications. RESULTS: Over 41,000 members
were included in the study, about half male and female.
About 2/3 were 45 or older. Approximately 21,000
(52%) had 0 comorbidities, 12,000 (29%) had 1, and
7800 (19%) had 1; 92% of those 18 had 0 comor-
bidities; 65% of those 18–44 did; 47% of those 45–64
did; 34% of those 65 did. Similarly, 0.3% of those
18 had 1 comorbidity; 10% of those 18–44s, 21% of
No 
complications
Only 
macrovascular 
complications
Time since diagnosis 
of diabetes 6.5 8.4
Percentage of patients 
hospitalized 14% 26%
Number of days in hospital 
per patient and year 2.0 6.5
Hospitalization costs per 
patient and year [DM] 1,007 3,832
Total costs per patient 
and year [DM] 3,370 6,723
Only 
microvascular 
complications
Macro  
microvascular 
complications
Time since diagnosis of 
diabetes 10.6 12.6
Percentage of patients 
hospitalized 24% 41%
Number of days in hospital 
per patient and year 6.7 11.3
Hospitalization costs per 
patient and year [DM] 3,150 6,867
Total costs per patient 
and year [DM] 6,563 11,034
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those 45–64s, and 30% of those 65. The mean annual
cost was $2,200; with 0 comorbidities: $1,200; with 1:
$2,000; with 1: $5,200. The R2 for the regression with-
out complications 0.0085 (0.85% of log charges ex-
plained by age and gender). The R2 with complications
was 0.1121 (11% explained by age, gender and compli-
cations). This increase was highly significant (P  0.001).
CONCLUSIONS: Costs increased 13 times more due to
complications than age on a log scale. Substantial savings
may be realized by MCOs who manage their member’s
diabetes well.
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Complications of Type 2 diabetes mellitus (DM) increase
costs to the healthcare provider. Age is correlated with
complications as well as costs. OBJECTIVE: To estimate
diabetes-related costs due to complications separately
from age. METHODS: Members with Type 2 DM were
selected by ETG group from PharMetric’s Integrated
Outcomes database during 1997. Charges to the mem-
ber’s MCO for ED, pharmacy, in- and out-patient ser-
vices were tallied over CY 1997. Members were classi-
fied: (1) as having 0,1, or 1 complications (nephropathy,
retinopathy, neuropathy, or CAD), and (2) by age: 18,
18–44, 45–64, or 65. A regression of age and gender
on ln(charges) was compared to a regression of age, gen-
der, and complications. RESULTS: Over 124,000 mem-
bers were included in the study, about half male and fe-
male. About 85% were 45 or older. Approximately
82,000 (66%) had 0 comorbidities, 32,500 (26%) had 1,
and 10,000 (8%) had 1; 92% of those 18 had 0 co-
morbidities; 83% of those 18–44 did; 70% of those 45–
64 did; 52% of those 65 did. Similarly, 0.4% of those
18 had 1 comorbidity; 2.5% of those 18–44s, 6.6%
of those 45–64s, and 13% of those 65. The mean an-
nual cost was $820; with 0 comorbidities: $575; with 1:
$1,000; with 1: $2,300. The R2 for the regression with-
out complications 0.0059 (0.6% of log charges explained
by age and gender). The R2 with complications was
0.0487 (5% explained by age, gender and complica-
tions). This increase was highly significant (P  0.001).
CONCLUSIONS: Costs increased 8 times more due to
complications than age on a log scale. Substantial savings
may be realized by MCOs who manage their member’s
diabetes well.
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Diabetic foot ulcers are a common problem and result in
more than 50,000 lower extremity amputations each
year in the United States. Studies have suggested that be-
tween 25% and 50% of costs related to inpatient diabe-
tes care may be directly attributable to the diabetic foot.
OBJECTIVE: To compare the cost-effectiveness of treat-
ment with standard Wound Care Center (WCC) care
with treatment with Platelet Releasate (PR), an autolo-
gous product that provides concentrated platelet-derived
growth factor directly to the wound. METHODS: Our
analysis is based on effectiveness data from a database
created by Curative Health Services that includes data on
over 26,500 patients with diabetic neuropathic foot ul-
cers. Effectiveness was assessed as percentage of ulcers
healed at 32 weeks. Cost estimates were derived from the
Medicare Resource-Based Relative Value Scale. A sensi-
tivity analysis was conducted by adjusting several of the
variables associated with the cost-effectiveness equation.
RESULTS: Baseline cost for 32 weeks of therapy was
$2880.01 for WCC care (n  14,735) and $5680.01 for
PR (n  4701). Baseline effectiveness (with 95% confi-
dence intervals) for WCC and PR care were 38.0 (37.2,
38.8) and 48.4 (46.9, 49.8) respectively. The cost-effec-
tiveness ratio for PR vs WCC care was 269.23. This ratio
represents the marginal cost (in 1999 US dollars) of in-
creasing the chance of healing at 32 weeks by 1% by us-
ing PR rather than WCC care. CONCLUSIONS: While
PR is more expensive than WCC care, it does provide a
27% improvement in baseline healing at 32 weeks, and
the incremental increased cost must be weighed against
the substantial economic and psychological impact of
lower extremity amputation.
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Cost savings associated with detection and treatment of
diabetic eye disease has been well documented. However,
the cost-effectiveness of retinopathy screening in pediat-
ric patients with type I diabetes mellitus remains unclear.
In 1998, the Academy of Pediatrics released a new policy
regarding the ophthalmologic examination schedule for
